Category: Uncategorized

  •     By Mark Chael — As Patent Docs has previously reported (here and here), the USPTO recently held a customer partnership meeting for the biotech, chemical, and pharmaceutical art groups.  Of the many interesting and informative presentations and discussions from the meeting, those of us that prosecute patent applications directed to oligonucleotide, protein, and…

  •     By Kevin E. Noonan — Last week, Simran Trana (at right), director of Purdue Research Foundation’s Office of Technology Commercialization acknowledged the 800 lb. gorilla that everyone talking about patent reform has been ignoring.  Speaking on a panel discussing patent reform legislation at BIO 2007 in Boston, Ms. Trana said that the need…

  •     By Kevin E. Noonan — Lost in the reaction to KSR Int’l Co. v. Teleflex Inc. two weeks ago was the Court’s decision in Microsoft Corp. v. AT&T Corp., rendered on the same day.  While not directed to a biotechnology invention, the case has interesting implications for the relationship between activities overseas and…

  •     By Kevin E. Noonan — On Tuesday, the U.S. Department of Justice (DOJ) and Federal Trade Commission (FTC) released an extensive (218 page) report on their analysis of the relationship between antitrust law and patent law (see "Antitrust Enforcement and Intellectual Property Rights: Promoting Innovation and Competition").  And in what may come as…

  • The folks at FedCirc.us have announced that a new search feature was implemented at the FedCirc.us site this morning. The new search feature gives readers access to FedCirc.us’ own Federal Circuit case summaries as well as to commentary and summaries from leading online commentators. We are flattered that FedCirc.us has decided to add the Patent Docs…

  •     By Bradley Crawford — In 1998, the Administrative Council of the European Patent Organisation, seeking to update the European Patent Convention (EPC), agreed on a catalog of potential revisions (see "EPC 2000").  A Task Force was then formed to prepare detailed proposals for revision of the EPC, which were examined and refined in…

  •      By Kevin Noonan It isn’t often that you hear someone defend so-called "patent trolls."  With the exception of publications directed towards the patent bar, most mainstream media are content to parrot the idea that anyone (other than a large manufacturing company) who asserts its patents in court is merely a "troll" trying to…

  •     By Kevin Noonan Recently, patenting human DNA has been the subject of questionable legislation and alarmist opinion pieces in the U.S.  Meanwhile, a team of British researchers has assessed the past, present, and likely future of gene patenting worldwide, and has come to dramatically different conclusions. The study, by members of the Science…

  •     By Kevin Noonan Much has been written in the comments to my response to Michael Crichton’s recent OpEd piece in The New York Times.  In order to open up the debate to those who haven’t read the comments, here is a thought experiment: You isolate a petrochemical with excellent lubrication qualities.  It is…

  •     By Kevin Noonan Michael Crichton has always hated – or feared – technology.  In his novels The Andromeda Strain, The Terminal Man, and Jurassic Park, he has been a technology Cassandra, a modern-day Luddite warning that technology would get us if we weren’t very careful.  And while space viruses, inhuman cyborgs, and thunder…